Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept + PDT for PCV in Pachychoroid
NCT04075188Completed
- Sponsor
- Policlinico Paolo Giaccone
- Start
- Sep 2017
- Primary completion
- Jun 2018
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Open-label, single-arm trial of aflibercept in polypoidal choroidal vasculopathy (PCV), sponsored by Policlinico Paolo Giaccone. Primary endpoints: Corrected Distance Visual Acuity at 12 months, Disease Activity at 12 months and 2 more. Started Sep 2017; status: completed.
02
Drugs
aflibercept
03
Conditions
polypoidal choroidal vasculopathy (PCV)
Beyond the preview
Go deeper on NCT04075188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04075188.